bexagliflozin
Trade name: Brenzavvy
Small moleculeapproved
Approved
Jan 20, 2023
Clinical trial activity
18 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
8
Phase 2
8
Phase 3
8
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01029704)
Timeline
2010s
Indications
Approved for
Mechanism of action
- Sodium/glucose cotransporter 2INHIBITOR
SLC5A2 inhibitor
INHIBITOR
Approval history
- approvedJan 20, 2023
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O- Mol. weight
- 464.94 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1808388 ↗
Also known as
- bexagliflozin
- bexagliflozin
- bexagliflozin
- bexagliflozin
- egt0001442
- egt0001442
- egt-0001442
- egt-0001442
- egt-1442
- egt-1442
- thr-1442
- thr-1442
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05369078 | Phase 1 | Dec 1, 2021 | Newsoara Biopharma Co., Ltd. |
| NCT03417076 | Phase 1 | Aug 1, 2018 | Harvard University, Theracos |
| NCT03557658 | Phase 1 | Jul 26, 2018 | Theracos |
| NCT03259789 | Phase 3 | Nov 28, 2017 | Theracos |
| NCT03514641 | Phase 2/Phase 3 (Phase 3) | Oct 18, 2017 | Harvard University, Theracos |
| NCT03296800 | Phase 1 | Sep 27, 2017 | Harvard University, Theracos |
| NCT03115112 | Phase 3 | Aug 1, 2017 | Theracos |
| NCT03197324 | Phase 1 | Jul 3, 2017 | Harvard University, Theracos |
| NCT03167411 | Phase 1 | Jun 20, 2017 | Harvard University, Theracos |
| NCT02956044 | Phase 1 | Nov 1, 2016 | Harvard University, Theracos |
| NCT02836873 | Phase 3 | Sep 1, 2016 | Harvard University, Theracos |
| NCT02769481 | Phase 3 | Aug 1, 2016 | Theracos |
| NCT02820298 | Phase 1 | Jun 1, 2016 | Davita Clinical Research, Theracos |
| NCT02715258 | Phase 3 | Mar 1, 2016 | Theracos |
| NCT02558296 | Phase 3 | Oct 1, 2015 | Theracos |
| NCT02390050 | Phase 2/Phase 3 (Phase 3) | May 1, 2015 | Theracos |
| NCT01377844 | Phase 2 | Dec 1, 2011 | Harvard University, Theracos |
| NCT01029704 | Phase 2 | Dec 1, 2009 | Harvard University, Theracos |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theracos | For profit | 17 | 17 | 3 | 2009 |
| Harvard University | Academic/Hospital | 9 | 0 | 3 | 2009 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2016 |
| Newsoara Biopharma Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1